AIkido Pharma Inc (AIKI)

[mining101]

Breakout

[Taurus69]

$aiki $0.5189 ^ 0.0095 (1.86%)
Volume: 1,194,474 @11/25/20 5:53:27 PM EST

[mining101]

Big day tomorrow - or not?

[mining101]

Who is picking more at the bottom of 50 cents

[Taurus69]

$aiki $0.538 ^ 0.0299 (5.88%)
Volume: 1,385,069 @11/13/20 4:20:09 PM EST

[mining101]

Move on or up. Let’s go Aiki

[elkonig]

Does this garbage scam ticker AIKI have to do a reverse split almost every year so it can stay on the NASDAQ?

[ttottip]

Great news! We will see the $0.6's today.

[ttottip]

Good morning all! Is something brewing here?

[Taurus69]

$aiki $0.5225 v -0.0115 (-2.15%)
Volume: 668,799 @11/10/20 4:17:06 PM EST

[Carioca]

Pooosh

[Taurus69]

$aiki $0.5032 v -0.0217 (-4.13%)
Volume: 961,225 @10/30/20 7:56:27 PM EDT

[$DDKING]

Yep I guess Reverse Split is happening fml all good it was a good trade

[mick]

very disappointed wit mgmt

[Carioca]

Let it ride or
Why didn’t you sell going south, peasants

[geocam]

$AIKI Note: Reverse Split vote Nov. 17

Proxy Statement (definitive) (def 14a)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159175042

NOTICE OF 2020 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON NOVEMBER 17, 2020



October 5, 2020



To our Stockholders:



Notice is hereby given that the 2020 Annual Meeting of Stockholders (the “Annual Meeting”) of AIkido Pharma Inc., a Delaware corporation (the “Company,” “AIkido Pharma Inc.,” “AIkido”, “our,” “we” or “us”), will be held as a “virtual meeting” via live audio webcast on Tuesday, November 17, 2020, at 9:00 a.m. Pacific Time/12:00 p.m. Eastern Time for the following purposes, as more fully described in the accompanying proxy statement (the “Proxy Statement”):



(1) To approve and adopt a proposal to amend our Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to effect a reverse stock split of our common stock at a ratio up to one-for-ten (1-for-10) (the “Reverse Split”), with the exact ratio to be set within that range at the sole discretion of our board of Directors (the “Board”) without further approval or authorization of our stockholders before the filing of an amendment to the Certificate of Incorporation effecting the proposed reverse stock split;

[justradethem]

TOMORROW. SHE'LL FLY. NO GET RICH QUICK FOLKS ON THIS BOARD...LOL

[mining101]

Need to go above 80

[justradethem]

HEADING NORTH ON A BAD DAY BABY..LOL

[mining101]

Who is selling at these levels?!

[D-bol]

What we think Mick is this ever going to move?

[mick]

Alkido Pharma Inc (AIKI)
0.575 ? -0.0051 (-0.88%)
Volume: 309,578 @10/23/20 7:11:37 PM EDT
Bid Ask Day's Range
0.42 0.7 0.57 - 0.5885
AIKI Detailed Quote

[Taurus69]

$aiki $0.5898 v -0.0172 (-2.83%)
Volume: 720,394 @10/02/20 7:43:19 PM EDT

[Viewmont]

Been pretty quite AIKI.

[Viewmont]

Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2)
Initial data reports one of the most critical genes for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003

(PRNewsfoto/Hoth Therapeutics Inc.)
NEWS PROVIDED BY

Hoth Therapeutics, Inc.
Sep 24, 2020, 08:38 ET

SHARE THIS ARTICLE


NEW YORK, Sept. 24, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced completing testing to examine the ability of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.

Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and Hoth Senior Scientific Advisor, led the first phase of the study. "Thanks to Dr. Zippin and his team, we have gained insight and gathered significant data with regards to the significance of HT-003 in blocking acne pathogenic gene expression," stated Robb Knie, CEO of Hoth Therapeutics. "We will continue to monitor the data at lower doses and move onto the testing of rodent skin and carcinogenesis."

Initial data from the first phase of the research reports that one of the most critical genes for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003. In addition, HT-003 at doses as high as 50 µM led to no observable toxicity. During the next phase of the research, Dr. Zippin will identify the minimal effective dose required to block TLR2 signaling in response to a broad range of bacteria derived agonists to further elucidate the pathway.

"The ability of HT-003 to potently inhibit TLR2 expression suggests that this drug will not only be effective for acne but may also help a broad range of patients suffering from disease driven by over active inflammatory responses to bacteria," stated Dr. Zippin.

Once HT-003 biomarkers have been identified using thein vitro human keratinocytes models, testing will move onto into live rodents.

About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit https://ir.hoththerapeutics.com/.

[Viewmont]

AIkido Pharma Announces Update On Its Use Of Artificial Intelligence
Development of Products, Tools, and Technologies to Accelerate Development of Key Marker Panels for the Personalized Treatment of PDA

(PRNewsfoto/AIkido Pharma Incorporated)
NEWS PROVIDED BY

AIkido Pharma Inc.
Sep 18, 2020, 10:00 ET

SHARE THIS ARTICLE


NEW YORK, Sept. 18, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) today announced that its work with research partner, Cogia BioTech LTD (www.cogia.de), has delivered several key updates on efforts to accelerate the study of PDA (Pancreatic Ductal Adenocarcinoma) treatments. As previously reported, the Company executed a Scientific Research Agreement with The University of Texas Southwestern Medical Center and Cogia to use machine learning to find genetic markers in people that indicate an increased risk of developing pancreatic cancer.

Cogia Biotech, a Big-data, Artificial Intelligence (AI), and Machine Learning (ML) software company committed to using powerful AI engines and algorithms to develop compelling outcomes in drug development, released a comprehensive progress report to AIkido which included:

The identification of clusters of markers that interact in signaling pathways affecting PDA survival.
The development of products and tools to provide extensive information on PDA markers to guide personalized medicine.
The assembly of survival associations of individual markers from ONCOLNC.org into sets that will help identify novel targets in PDA.
Information about gene and protein function in human PDA patients and human PDA cancer cell lines to help prioritize individual diagnostic markers.
Anthony Hayes, CEO of AIkido stated, "We are extremely pleased with the progress that Cogia has made in this research project, and are enthusiastic about their continued efforts to develop panels of markers that will rapidly identify patients who have initiated early events in pancreatic cancer. Cogia's Diagnostic Assay Application and Prognostic Marker Characterization Application products assemble essential information on antibodies specific to the respective proteins for more than 20,000 antibody reagents and utilizes the unsupervised learning protocols of the Cogia AI/ML engine to identify clusters of similarly expressed genes, and their association with PDA subtypes. These tools establish the building blocks of what we continue to believe will be an even broader set of usable full-service products and tools for ongoing and more expanded PDA diagnostics, prognostics, and therapeutics.

About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

[Viewmont]

AIkido Pharma Announces Peer-Reviewed Publication of Positive Results from Study of Antiviral Compounds Licensed from University of Maryland, Baltimore
Findings Demonstrate Ability of 17 FDA Approved Drugs to Inhibit SARS-CoV-2 (Coronavirus)

(PRNewsfoto/AIkido Pharma Incorporated)
NEWS PROVIDED BY

AIkido Pharma Inc.
Sep 11, 2020, 09:00 ET

SHARE THIS ARTICLE


NEW YORK, Sept. 11, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the publication of positive results from a study of antiviral activity of FDA approved drugs in a peer-reviewed article in the Journal of Virology. The publication cites that 17 of the 20 FDA-approved drugs studied inhibit SARS-CoV-2 at non-cytotoxic concentrations.

Mr. Anthony Hayes, CEO of AIkido stated, "The publication of a peer-reviewed study in a highly-revered journal represents additional validation of University of Maryland, Baltimore's (UMB) antiviral platform. The results clearly articulate the technology we have optioned from the university, and we are encouraged by the opportunities we may be able to pursue with the platform".

In the article, which was co-authored by investigators from the University of Maryland School of Medicine, 17 of the 20 FDA approved drugs against SARS-CoV-2 that also inhibit SARS-CoV and MERS-CoV inhibit SARS-CoV-2 at non-cytotoxic concentrations suggesting these may have pan-anti-coronaviral activity.

The full article is available at https://jvi.asm.org/content/early/2020/08/13/JVI.01218-20.

The Company previously executed a Master License Agreement with UMB for specific antiviral compounds discovered by UMB that seek to inhibit replication of multiple viruses, including Influenza virus, SARS-CoV, MERS-CoV, Ebolavirus and Marburg virus. The technology is covered by two patent applications already on file with the United States Patent and Trademark Office. The Company previously executed a Sponsored Research Agreement with UMB to support the development of the technology.

About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

[Viewmont]

AIKIDO PHARMA INC.
Dear Stockholder:
You are cordially invited to attend AIkido Pharma Inc.’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on Tuesday, November 17, 2020, at 9:00 a.m. Pacific Time/12:00 p.m. Eastern Time. The formal meeting notice and proxy statement for the Annual Meeting are attached.

The Annual Meeting will be a completely virtual meeting of stockholders, which will be conducted via live webcast. You will be able to attend the Annual Meeting online, vote and submit your questions during the Annual Meeting by visiting www.virtualshareholdermeeting.com/AIKI2020.

https://www.otcmarkets.com/filing/html?id=14404041&guid=y5C6Ue0BaFkq7Zh

https://aikidopharma.com/

https://aikidopharma.com/portfolio/

https://aikidopharma.com/scientific-advisory-board/

https://ir.aikidopharma.com/sec-filings/

One Rockefeller Plaza
11th Floor
New York, NY 10020

Share Structure
Market Cap Market Cap
21,297,842
09/29/2020
Authorized Shares
200,000,000
03/02/2020
Outstanding Shares
34,920,219
08/05/2020
Restricted
Not Available
Unrestricted
Not Available
Held at DTC
Not Available
Float
Not Available

https://www.otcmarkets.com/stock/AIKI/news/story?e&id=1699606

Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2)
Initial data reports one of the most critical genes for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003
NEW YORK, Sept. 24, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced completing testing to examine the ability of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.


Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and Hoth Senior Scientific Advisor, led the first phase of the study. "Thanks to Dr. Zippin and his team, we have gained insight and gathered significant data with regards to the significance of HT-003 in blocking acne pathogenic gene expression," stated Robb Knie, CEO of Hoth Therapeutics. "We will continue to monitor the data at lower doses and move onto the testing of rodent skin and carcinogenesis."

Initial data from the first phase of the research reports that one of the most critical genes for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003. In addition, HT-003 at doses as high as 50 µM led to no observable toxicity. During the next phase of the research, Dr. Zippin will identify the minimal effective dose required to block TLR2 signaling in response to a broad range of bacteria derived agonists to further elucidate the pathway.

"The ability of HT-003 to potently inhibit TLR2 expression suggests that this drug will not only be effective for acne but may also help a broad range of patients suffering from disease driven by over active inflammatory responses to bacteria," stated Dr. Zippin.

Once HT-003 biomarkers have been identified using thein vitro human keratinocytes models, testing will move onto into live rodents.

[Viewmont]

I added a bunch today also!

[mining101]

What are you talking pennybuster

[Pennybuster]

In a starter position on this one.

[ttottip]

Something big is happening here!

[mining101]

Nothing?

[mining101]

Now I am also convinced with that chart. Double bottom etc

[nssrr5]

I missed the .65 spike but nice to see. Lets get this back over a buck where it belongs.

[mining101]

Rather soon a double bottom - if

[$treet $inatra]

AIKI huge reversal from the highs today. Talking about Dilution jeez~

[mining101]

Are you just guessing? Back below 60 Cent

[Viewmont]

Yup, let's see where it goes. Hopefully $1.

[nssrr5]

Of course.

[mining101]

If you talk about a dollar - is there maybe even more value than that?

[nssrr5]

Looking good again this morning. Dollar soon

[nssrr5]

Way oversold.

[Viewmont]

OK thanks. Couldn't find news. Good luck!

[mining101]

I would say oversold on mini volume

[mining101]

Good to see - sometimes difficult to get the right timing

[Viewmont]

What's moving it, any news?

[nssrr5]

.70 after hours. Dollar soon

[mining101]

Looks good so far - why are you so sure about it?

[nssrr5]

Bottom was Friday at .54. It will hold.